The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Share News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.75
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (5.263%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.75
ABDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Abingdon Health progresses at-home STD test programme

Mon, 25th Mar 2024 15:27

(Sharecast News) - Abingdon Health updated the market on the development of self-tests for sexually transmitted diseases (STDs) on Monday, announcing the completion of the 'design freeze' stage for four key tests in collaboration with Devyn.

The AIM-traded firm said the tests, covering HIV, hepatitis B, hepatitis C and syphilis, were developed under a CDMO contract with Devyn's subsidiary 'Find Out From Home'.

It said the development was part of a broader strategic partnership between Abingdon Health and Find Out, formalised through a service for equity agreement.

Under the agreement, Abingdon would continue to offer regulatory and technical transfer services, and also take a significant minority equity stake in Find Out.

As the exclusive manufacturer and regulatory partner for the products, Abingdon Health said it would lead distribution in the UK and Europe.

The initiative could tap into a growing demand for STD testing, with the global market expected to reach $145bn by 2035, driven by increasing STD cases among young adults and a lack of awareness about safe sex practices.

Abingdon said its chief executive officer Chris Yates would join the board of Find Out, further cementing the strategic alignment between the two entities.

"We are delighted to announce the strategic partnership with Find Out From Home," said chief executive officer Chris Yates.

"We have been working with the team at Find Out for the past year and are pleased that the initial set of four STD lateral flow tests have now reached design freeze."

Yates said the company was looking forward to deepening its partnership with Find Out, and ultimately launching the rapid STD tests into the European market.

"We believe there is a significant unmet need for accurate, user-friendly STD lateral flow tests and this partnership underlines our approach in supporting customers on bringing innovative lateral flow tests from "idea to commercial success."

At 1500 GMT, shares in Abingdon Health were up 8.11% at 10p.

Reporting by Josh White for Sharecast.com.

More News
9 Feb 2021 11:18

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

Read more
8 Feb 2021 11:20

Abingdon Health Shares Slip On Media Speculation Around Covid Tests

Abingdon Health Shares Slip On Media Speculation Around Covid Tests

Read more
27 Jan 2021 19:17

IN BRIEF: Abingdon Health Says No More UK Government Orders Planned

IN BRIEF: Abingdon Health Says No More UK Government Orders Planned

Read more
29 Dec 2020 10:28

Abingdon Health Continues Work With Regulator For Covid Test Approval

Abingdon Health Continues Work With Regulator For Covid Test Approval

Read more
15 Dec 2020 14:14

IN BRIEF: Abingdon Health Raises GBP22 Million In AIM IPO

IN BRIEF: Abingdon Health Raises GBP22 Million In AIM IPO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.